| CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma K Rejeski, A Perez, P Sesques, E Hoster, C Berger, L Jentzsch, ... Blood, The Journal of the American Society of Hematology 138 (24), 2499-2513, 2021 | 260 | 2021 |
| Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas RD Morin, S Assouline, M Alcaide, A Mohajeri, RL Johnston, L Chong, ... Clinical cancer research 22 (9), 2290-2300, 2016 | 235 | 2016 |
| A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma E Bachy, S Le Gouill, R Di Blasi, P Sesques, G Manson, G Cartron, ... Nature medicine 28 (10), 2145-2154, 2022 | 217 | 2022 |
| Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements P Sesques, NA Johnson Blood, The Journal of the American Society of Hematology 129 (3), 280-288, 2017 | 174 | 2017 |
| Commercial anti‐CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center P Sesques, E Ferrant, V Safar, F Wallet, J Tordo, A Dhomps, L Karlin, ... American journal of hematology 95 (11), 1324-1333, 2020 | 117 | 2020 |
| Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow … AM Spanjaart, P Ljungman, R de La Camara, G Tridello, ... Leukemia 35 (12), 3585-3588, 2021 | 96 | 2021 |
| Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis R Di Blasi, S Le Gouill, E Bachy, G Cartron, D Beauvais, F Le Bras, ... Blood, The Journal of the American Society of Hematology 140 (24), 2584-2593, 2022 | 68 | 2022 |
| Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study É Azoulay, P Castro, A Maamar, V Metaxa, AG De Moraes, L Voigt, ... The Lancet Haematology 8 (5), e355-e364, 2021 | 59 | 2021 |
| An 18F-FDG-PET maximum standardized uptake value> 10 represents a novel valid marker for discerning Richter’s Syndrome AS Michallet, P Sesques, KG Rabe, E Itti, J Tordot, C Tychyj-Pinel, ... Leukemia & lymphoma 57 (6), 1474-1477, 2016 | 59 | 2016 |
| Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified E Bourbon, D Maucort-Boulch, J Fontaine, C Mauduit, P Sesques, V Safar, ... Blood Advances 5 (16), 3227-3239, 2021 | 42 | 2021 |
| Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy K Rejeski, A Burchert, G Iacoboni, P Sesques, L Fransecky, V Bücklein, ... Blood advances 6 (16), 4719-4725, 2022 | 41 | 2022 |
| First‐line treatment of double‐hit and triple‐hit lymphomas: survival and tolerance data from a retrospective multicenter French study M Laude, L Lebras, P Sesques, H Ghesquieres, S Favre, K Bouabdallah, ... American journal of hematology 96 (3), 302-311, 2021 | 36 | 2021 |
| Prognostic impact of 18F-FDG PET/CT in patients with aggressive B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T cells P Sesques, J Tordo, E Ferrant, V Safar, F Wallet, A Dhomps, G Brisou, ... Clinical nuclear medicine 46 (8), 627-634, 2021 | 35 | 2021 |
| The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma K Rejeski, DK Hansen, R Bansal, P Sesques, S Ailawadhi, JM Logue, ... Journal of Hematology & Oncology 16 (1), 88, 2023 | 34 | 2023 |
| Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study V Camus, C Rossi, P Sesques, J Lequesne, D Tonnelet, C Haioun, ... Blood advances 5 (19), 3862-3872, 2021 | 30 | 2021 |
| Metagenomic next-generation sequencing reveals individual composition and dynamics of anelloviruses during autologous stem cell transplant recipient management A Bal, C Sarkozy, L Josset, V Cheynet, G Oriol, J Becker, G Vilchez, ... Viruses 10 (11), 633, 2018 | 28 | 2018 |
| COVID‐19: What type of cytokine storm are we dealing with? G Monneret, I Benlyamani, M Gossez, JF Bermejo‐Martin, ... Journal of medical virology 93 (1), 197, 2021 | 22 | 2021 |
| Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients P Sesques, E Bachy, E Ferrant, V Safar, M Gossez, F Morfin-Sherpa, ... Cancer Cell 40 (3), 236-237, 2022 | 21 | 2022 |
| First results of DLBCL patients treated with CAR‐T cells and enrolled in DESCAR‐T registry, a French real‐life database for CAR‐T cells in hematologic malignancies S Le Gouill, E Bachy, R Di Blasi, G Cartron, D Beauvais, F Le Bras, ... Hematological Oncology 39, 2021 | 19 | 2021 |
| Central nervous system involvement in chronic lymphocytic leukemia: uncommon manifestation with undefined therapeutic management C Rossi, G Brisou, L Baseggio, J Roch, V Safar, L Karlin, P Sesques, ... Leukemia & Lymphoma 55 (8), 1939-1941, 2014 | 18 | 2014 |
